The future for pharmacovigilance and pharmacoepi-demiology should be bright.
CONCLUSIONS
The
future for pharmacovigilance and pharmacoepi-demiology should be bright. That
there is a need for this type of information is without doubt. The original
vision of Professor Finney that it should be possi-ble to uncover most
significant drug-induced disor-ders by systematic analysis of routine
information collected as part of everyday clinical practice is on the verge of
fulfillment. Funding is a chronic problem for workers in the field. The
pharmaceutical indus-try cannot be expected to fund all this effort. So far it
has contributed the lion’s share of the initia-tive. Research Councils and
others involved in the public conduct of affairs also need to contribute if the
systems we have evolved to date are to realise their full potential. The signs
are good with the Medicines and Healthcare products Regulatory Agency in the
United Kingdom now contributing substantially to the development of the General
Practice Research Database.
Related Topics
TH 2019 - 2023 pharmacy180.com; Developed by Therithal info.